Paper6131277
JMS, successor to cisplatin in advanced ovarian carcinoma?
Wiltshaw E and 4 others. Lancet, 1983. Cited by 53 papers, by iCite.
Cite this record
ConductScience Library. JMS, successor to cisplatin in advanced ovarian carcinoma? Papers, record 6131277. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6131277
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Organoplatinum Compounds | Major topic |
| Ovarian Neoplasms | Major topic |
| Carboplatin | |
| Cisplatin | |
| Clinical Trials as Topic | |
| Female | |
| Humans | |
| Prospective Studies | |
| Random Allocation |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40956032 | Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism. | Cancer Med | 2025 | https://conductscience.org/library/papers/40956032 | PubMed |
| 35477416 | Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35477416 | PubMed |
| 7693428 | New cisplatin analogues in development. A review. | Drugs | 1993 | https://conductscience.org/library/papers/7693428 | PubMed |
| 6392147 | A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. | Invest New Drugs | 1984 | https://conductscience.org/library/papers/6392147 | PubMed |
| 6380788 | Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8). | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6380788 | PubMed |
| 6371017 | Chemotherapy in advanced ovarian cancer. | J Cancer Res Clin Oncol | 1984 | https://conductscience.org/library/papers/6371017 | PubMed |
| 6371015 | Developing new drugs for ovarian cancer: a challenging task in a changing reality. | J Cancer Res Clin Oncol | 1984 | https://conductscience.org/library/papers/6371015 | PubMed |
| 3555590 | Haematological toxicity of carboplatin in rats. | Br J Cancer | 1987 | https://conductscience.org/library/papers/3555590 | PubMed |
| 3542270 | Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3542270 | PubMed |
| 3539384 | Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3539384 | PubMed |
| 3293841 | In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3293841 | PubMed |
| 3293840 | Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3293840 | PubMed |
| 3282706 | Potentiation of platinum analogue cytotoxicity by hyperthermia. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3282706 | PubMed |
| 2192812 | Carboplatin is ototoxic. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2192812 | PubMed |
| 1315566 | The interaction of platinum antitumour drugs with mouse liver mitochondria. | Int J Exp Pathol | 1992 | https://conductscience.org/library/papers/1315566 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6131277
GET https://conductscience.org/api/papers/v1/6131277/authors